Logo image of HIPO

HIPPO HOLDINGS INC (HIPO) Stock Fundamental Analysis

NYSE:HIPO - New York Stock Exchange, Inc. - US4335392027 - Common Stock - Currency: USD

27.09  -1.2 (-4.24%)

After market: 27.09 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to HIPO. HIPO was compared to 143 industry peers in the Insurance industry. While HIPO has a great health rating, there are worries on its profitability. HIPO is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year HIPO has reported negative net income.
HIPO had a positive operating cash flow in the past year.
HIPO had negative earnings in each of the past 5 years.
In the past 5 years HIPO always reported negative operating cash flow.
HIPO Yearly Net Income VS EBIT VS OCF VS FCFHIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.22%, HIPO is doing worse than 95.74% of the companies in the same industry.
HIPO has a Return On Equity of -38.91%. This is amonst the worse of the industry: HIPO underperforms 95.04% of its industry peers.
Industry RankSector Rank
ROA -8.22%
ROE -38.91%
ROIC N/A
ROA(3y)-20.59%
ROA(5y)-24.99%
ROE(3y)-57.33%
ROE(5y)-68.73%
ROIC(3y)N/A
ROIC(5y)N/A
HIPO Yearly ROA, ROE, ROICHIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

HIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIPO Yearly Profit, Operating, Gross MarginsHIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300 -400

7

2. Health

2.1 Basic Checks

HIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
HIPO has more shares outstanding than it did 1 year ago.
There is no outstanding debt for HIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HIPO Yearly Shares OutstandingHIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M
HIPO Yearly Total Debt VS Total AssetsHIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.85, we must say that HIPO is in the distress zone and has some risk of bankruptcy.
HIPO's Altman-Z score of -0.85 is fine compared to the rest of the industry. HIPO outperforms 68.09% of its industry peers.
There is no outstanding debt for HIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.85
ROIC/WACCN/A
WACC9.06%
HIPO Yearly LT Debt VS Equity VS FCFHIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.06 indicates that HIPO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.06, HIPO belongs to the top of the industry, outperforming 92.20% of the companies in the same industry.
A Quick Ratio of 2.06 indicates that HIPO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.06, HIPO belongs to the best of the industry, outperforming 92.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 2.06
HIPO Yearly Current Assets VS Current LiabilitesHIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.27% over the past year.
The Revenue has grown by 84.92% in the past year. This is a very strong growth!
HIPO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.58% yearly.
EPS 1Y (TTM)56.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.09%
Revenue 1Y (TTM)84.92%
Revenue growth 3Y59.58%
Revenue growth 5YN/A
Sales Q2Q%65.51%

3.2 Future

Based on estimates for the next years, HIPO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.81% on average per year.
HIPO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.13% yearly.
EPS Next Y65.18%
EPS Next 2Y37.52%
EPS Next 3Y25.24%
EPS Next 5Y22.81%
Revenue Next Year83.59%
Revenue Next 2Y49.82%
Revenue Next 3Y37.42%
Revenue Next 5Y26.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HIPO Yearly Revenue VS EstimatesHIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
HIPO Yearly EPS VS EstimatesHIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -5 -10

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HIPO. In the last year negative earnings were reported.
Also next year HIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HIPO Price Earnings VS Forward Price EarningsHIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HIPO Per share dataHIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as HIPO's earnings are expected to grow with 25.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.52%
EPS Next 3Y25.24%

0

5. Dividend

5.1 Amount

HIPO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HIPPO HOLDINGS INC

NYSE:HIPO (2/21/2025, 8:25:38 PM)

After market: 27.09 0 (0%)

27.09

-1.2 (-4.24%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-06 2025-03-06/amc
Inst Owners41.3%
Inst Owner Change5.32%
Ins Owners11.37%
Ins Owner Change-0.21%
Market Cap659.91M
Analysts80
Price Target32.3 (19.23%)
Short Float %7.38%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.57%
Min EPS beat(2)3.04%
Max EPS beat(2)28.09%
EPS beat(4)3
Avg EPS beat(4)10.71%
Min EPS beat(4)-3.91%
Max EPS beat(4)28.09%
EPS beat(8)4
Avg EPS beat(8)-2.86%
EPS beat(12)4
Avg EPS beat(12)-18.39%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.62%
Max Revenue beat(2)-0.46%
Revenue beat(4)2
Avg Revenue beat(4)6.9%
Min Revenue beat(4)-0.62%
Max Revenue beat(4)14.46%
Revenue beat(8)5
Avg Revenue beat(8)6.69%
Revenue beat(12)6
Avg Revenue beat(12)4.31%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.15%
PT rev (3m)29.25%
EPS NQ rev (1m)1.79%
EPS NQ rev (3m)45.75%
EPS NY rev (1m)2.7%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.97
P/FCF N/A
P/OCF 122.21
P/B 2.02
P/tB 2.61
EV/EBITDA N/A
EPS(TTM)-5.51
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)0.22
OCFY0.82%
SpS13.74
BVpS13.4
TBVpS10.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.22%
ROE -38.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.59%
ROA(5y)-24.99%
ROE(3y)-57.33%
ROE(5y)-68.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.23%
Cap/Sales 4.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.06
Quick Ratio 2.06
Altman-Z -0.85
F-Score7
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)174.55%
Cap/Depr(5y)203.82%
Cap/Sales(3y)19.27%
Cap/Sales(5y)21.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.09%
EPS Next Y65.18%
EPS Next 2Y37.52%
EPS Next 3Y25.24%
EPS Next 5Y22.81%
Revenue 1Y (TTM)84.92%
Revenue growth 3Y59.58%
Revenue growth 5YN/A
Sales Q2Q%65.51%
Revenue Next Year83.59%
Revenue Next 2Y49.82%
Revenue Next 3Y37.42%
Revenue Next 5Y26.13%
EBIT growth 1Y59.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.29%
EBIT Next 3Y28.03%
EBIT Next 5Y21.86%
FCF growth 1Y93.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.19%
OCF growth 3YN/A
OCF growth 5YN/A